Stock Traders Buy Large Volume of EXACT Sciences Put Options (EXAS)
Shares of EXACT Sciences (NASDAQ:EXAS) were the target of some unusual options trading activity on Wednesday. Traders bought 5,569 put options on the stock, StockRatingsNetwork reports. This represents an increase of approximately 314% compared to the typical volume of 1,344 put options.
A number of analysts have recently weighed in on EXAS shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, August 12th. They now have a $20.00 price target on the stock, up previously from $19.00. Separately, analysts at Benchmark Co. upgraded shares of EXACT Sciences to a “buy” rating in a research note on Tuesday, August 12th. Finally, analysts at Jefferies Group raised their price target on shares of EXACT Sciences from $18.00 to $20.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. EXACT Sciences currently has a consensus rating of “Hold” and a consensus target price of $19.50.
EXACT Sciences (NASDAQ:EXAS) traded up 6.43% during mid-day trading on Wednesday, hitting $19.52. 5,200,062 shares of the company’s stock traded hands. EXACT Sciences has a 52 week low of $9.53 and a 52 week high of $19.15. The stock has a 50-day moving average of $16.58 and a 200-day moving average of $14.37. The company’s market cap is $1.619 billion.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 22nd. The company reported ($0.24) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.19) earnings per share. Analysts expect that EXACT Sciences will post $-1.14 EPS for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.